Clinical Laserthermia Systems AB (publ) announced that the Company has received additional orders from ClearPoint Neuro Inc. The order, which has a value of approximately SEK 7.5 million, is for ClearPoint Prism products and is part of ClearPoint Neuro's full market launch in North America, which began in early June this year, and follows previous orders that CLS received around the turn of the year 2023/2024 totaling approximately SEK 10.5 million. CLS's collaboration with ClearPoint Neuro Inc. aims to develop and commercialize a next-generation fully integrated laser therapy system for high-precision MRI-guided stereotactic laser ablation for use in neurosurgery. Through the integration of the companies' technologies into ONE product solution, users are offered the opportunity to identify, navigate and position sterile laser applicators in the target tissue in a streamlined simplified workflow, followed by MRI-guided monitoring and control of temperature development and ablation progress in the target tissue.

During the spring, the companies have also taken a number of decisive steps to, among other things, further strengthen the product offering and expand the market in the US, steps that include ClearPoint Neuro'sUS-FDA 510 (k) clearance for Prism®? Bone Anchor Accessory.